Alector downgraded to Neutral from Overweight at Cantor Fitzgerald

Cantor Fitzgerald downgraded Alector (ALEC) to Neutral from Overweight without a price target after the company’s INFRONT-3 trial of latozinemab failed to meet its primary endpoint with no directly positive benefit. Alector’s other programs are too early to value, the analyst tells investors in a research note.